.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

San Antonio Breast Cancer Symposium

Trastuzumab Biosimilar With PIK3CA Inhibitor Shows Efficacy in Advanced Breast Cancer

December 10th 2020

Article

Two studies of trastuzumab biosimilars have improved understanding of these medicines as monotherapy and in combination with other agents in metastatic breast cancer.

Biosimilar Conjugate Evaluated in HER2-Positive Patient Population

December 9th 2020

Article

Investigators explained the potential for durable antitumor efficacy in patients with human epidermal growth factor receptor 2 (HER2)-expressing or -driven tumors who have exhausted other treatment options.

Investigators Look to Cut Breast Cancer Recurrence With Posttrastuzumab Therapy

November 24th 2020

Article

GP2 peptide/G-CSF in HER2-equivocal and -positive breast cancer has shown promise.